Skip to main content
SCI logo

SCI — Investor Relations & Filings

Ticker · 4119 ISIN · TW0004119003 TW Manufacturing
Open in API
Filings indexed 1,697 across all filing types
Latest filing 2023-12-07 Director's Dealing
Country TW Taiwan
Listing TW 4119

About SCI

www.sci-pharmtech.com.tw

SCI Pharmtech, Inc. specializes in the research, development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and specialty chemicals. Established in 1987 and originally founded by the Swiss Siegfried Group, the company provides high-quality chemical solutions and custom manufacturing services to leading global pharmaceutical corporations across Europe, North America, and Japan. Its core operations encompass advanced chemical synthesis, process optimization, and large-scale production within GMP-compliant facilities. With a robust R&D infrastructure including specialized laboratories and pilot plants, the company delivers technical excellence in complex chemical processing. SCI Pharmtech maintains a strong focus on quality assurance and international regulatory compliance, positioning itself as a reliable partner for the global healthcare and life sciences sectors.

Recent filings

Filing Released Lang Actions
112年11月內部人持股異動(事後)
Director's Dealing Classification · 100% confidence The document consists of detailed tables listing shareholdings and changes in share ownership by insiders, including directors, managers, and their related parties. It includes data on shares held at appointment, changes during the month, and current holdings. This type of information corresponds to disclosures about personal share transactions by company directors and executives, commonly known as insider trading or director dealings. There is no indication of financial statements, earnings data, meeting materials, or other report types. The document is not an announcement of a report but a detailed disclosure itself. Therefore, the appropriate classification is Director's Dealing (DIRS).
2023-12-07 Chinese
112年11月董事會成員及持股
Director's Dealing Classification · 95% confidence The document contains detailed tabular data about shareholdings of company insiders, including directors, managers, and major shareholders. It lists current holdings, pledged shares, and related party holdings. The content is focused on insider share transactions and holdings rather than financial results, management changes, or other corporate events. The document length is about 3,073 characters, which is relatively short and focused on insider shareholding information. This matches the definition of Director's Dealing (DIRS), which reports personal share transactions by company directors and executives. There is no indication of other report types such as financial reports, meeting materials, or announcements. Therefore, the appropriate classification is DIRS.
2023-12-07 Chinese
112年第3季財務報告書 — 202302_4119_AI1.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a consolidated financial report for the company 旭富製藥科技股份有限公司及子公司 covering the periods ending June 30, 2023 and June 30, 2022 (民國一一二年及一一一年第二季). It includes detailed financial statements such as the consolidated balance sheet, income statement, statement of changes in equity, cash flow statement, and extensive notes to the financial statements. The report also contains an auditor's review report (會計師核閱報告) indicating that the financial statements have been reviewed in accordance with review standards, not a full audit. The document references compliance with international accounting standards for interim financial reporting (IFRS 34) and is clearly a mid-year financial report. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is a full interim/quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2023-11-13 Chinese
112年第3季財務報告書 — 202301_4119_AIA.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Consolidated Financial Statements' with an 'Independent Auditors’ Review Report' for the three months ended March 31, 2023 and 2022. It includes detailed financial statements such as balance sheets, statements of comprehensive income, changes in equity, cash flows, and notes to the consolidated financial statements. The report is prepared in accordance with International Accounting Standard 34 'Interim Financial Reporting' and the Regulations Governing the Preparation of Financial Reports by Securities Issuers. The presence of an auditor's review report (not a full audit) and the focus on a three-month period indicates this is an interim financial report rather than a full annual report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2023-11-13 Chinese
112年第3季財務報告書 — 202301_4119_AI1.pdf
Regulatory Filings
2023-11-13 Chinese
112年第3季權益變動表
Interim / Quarterly Report Classification · 95% confidence The document contains detailed financial data related to changes in equity, including items such as common stock capital, capital surplus, legal surplus reserve, special surplus reserve, undistributed earnings, retained earnings, and other comprehensive income. The data is presented for the current period (first three quarters of the year) and the same period last year, with amounts in thousands of New Taiwan Dollars. The document is titled as a consolidated equity changes statement and includes detailed accounting items and balances. The length of the document is 3886 characters, which is relatively short but contains substantive financial data rather than just an announcement or certification. This type of detailed financial statement is typically part of an Interim / Quarterly Report (IR), as it covers a period shorter than a full fiscal year and includes actual financial data and analysis. Therefore, the document is best classified as an Interim / Quarterly Report (IR).
2023-11-10 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.